News
From Insulin to Ozempic, History of Novo Nordisk's CEOs
Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was spun off as a separate company, Novozymes A/S in 2000. In 2004, Levemir – a long-acting modern insulin – was launched.
Danish pharma group Novo Nordisk has revealed it is in exclusive negotiations that could result in the acquisition of a controlling stake in Biocorp, a French company that makes medical devices ...
Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history. The company’s ...
Bank of America analysts point out that currency hedging will help cushion the blow on Novo Nordisk's bottom line. They also pointed ... in a very simple device solution is very convenient for ...
at a 20% discount to Novo Nordisk’s brand. The new spending comes after announcements of 40 billion DKK in production investments in the last two years, including spending on a new facility in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback